CORRELATION OF TUMOR ABSORBED DOSES OF 177LU-DOTA-TATE TREATMENT WITH PRE-THERAPEUTIC GA68 DOTA-TATE PET/CT UPTAKE IN NEUROENDOCRINE TUMORS Abstract #588

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 aroused great interest. Estimation of actual radiation doses to tumors may help therapy planning.
Aim(s): Aim of the study was to compare tumor absorbed doses with pre-therapeutic Ga-68-DOTA-TATE-PET/CT uptake calculated from SUVvalues.
Materials and methods: PRRT results of patients (M/F:8/5,mean age:55.5±12.5) with inoperable NETs were retrospectively analyzed. Dosimetric calculations were performed using MIRD scheme Calculated tumor absorbed doses were compared with SUVmax of 68 Ga-DOTA-TATE-PET/CT.
Conference:
Category: Clinical
Presenting Author: Dr. Demirci Emre

To read results and conclusion, please login ...

Further abstracts you may be interested in

#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#516 Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT in Somatostatin Exopressing Organs and Tumors
Introduction: Octreotide derived radiolabelled peptides have been widely used for somatostatin receptor (sstr) imaging. Clinically used radiopeptides exclusively target sstr subtype 2. But radiolabeled Lanreotide has been claimed to bind sstr 2, 3 and 5.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Emre Demirci
Authors: Kabasakal L, Demirci E, Ocak M, Aygun A, ...
Keywords: Octreotide PET
#517 Initial Experience of Biological Stability and Image Timing of Ga-68 DOTANOC in Somatostatin Receptor (sstr) Expressing Organ and Tumor
Introduction: Since Ga68 DOTATATE has a high affinity to only sstr2 but no affinity to sstr3 and sstr5, Ga68 DOTANOC has been suggested to be a better radioligand with higher affinity to sstr3 and sstr5 and high affinity to sstr2, as well.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Emre Demirci
Authors: Demirci E, Kabasakal L, Ocak M, Aygun A, ...
Keywords: Octreotide PET
#590 Imaging of Metastatic-Recurrent Paragangliomas and Pheochromocytomas with Ga-68 DOTATATE PET/CT
Introduction: Approximately 73% of Pheochromocytomas(Pheo) and 93% of paragangliomas(PGL) express somatostatin receptors and Ga-68 DOTATATE PET/CT may have a role in metastatic PHEO/PGLs for determination of extent of disease.
Conference:
Category: Clinical
Presenting Author: Dr. emre demirci
Authors: demirci E, ocak M, kabasakal L, yeyin N, ...
#1534 Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)
Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Michela Del Prete